These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 21252717

  • 1. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sánchez JJ, Camps C.
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [Abstract] [Full Text] [Related]

  • 2. Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer.
    Camps C, Sirera R, Bremnes RM, Ródenas V, Blasco A, Safont MJ, Garde J, Juarez A, Caballero C, Sanchez JJ, Taron M, Rosell R.
    Anticancer Res; 2006 Feb; 26(6C):4905-9. PubMed ID: 17214360
    [Abstract] [Full Text] [Related]

  • 3. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C, Sriuranpong V, Tanasanvimon S, Chantranuwat P, Mutirangura A.
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [Abstract] [Full Text] [Related]

  • 4. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R, Vallbohmer D, Müller-Tidow C, Higashi H, Bollschweiler E, Warnecke-Eberz U, Brabender J, Baldus SE, Xi H, Berdel WE, Serve H, Hoelscher AH, Schneider PM.
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [Abstract] [Full Text] [Related]

  • 5. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M, Pujol JL, Lamy PJ, Bozonnat MC, Quantin X, Jacot W, Daurès JP.
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [Abstract] [Full Text] [Related]

  • 6. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D, Carbonelli C, De Franco S, Brini M, Sgarbi G, Lodi R.
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [Abstract] [Full Text] [Related]

  • 7. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.
    Pelosi G, Schianchi E, Dell'orto P, Veronesi G, Spaggiari L, Pasini F, Sozzi G, Brambilla E, Griso C, Viale G.
    Virchows Arch; 2006 Jan; 448(1):7-15. PubMed ID: 16193293
    [Abstract] [Full Text] [Related]

  • 8. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ.
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [Abstract] [Full Text] [Related]

  • 9. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M.
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [Abstract] [Full Text] [Related]

  • 10. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T, Krawczyk P, Nicoś M, Kuźnar-Kamińska B, Batura-Gabryel H, Milanowski J.
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [Abstract] [Full Text] [Related]

  • 11. Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer.
    Zalewska-Ziob M, Dobija-Kubica K, Biernacki K, Adamek B, Kasperczyk J, Bruliński K, Ostrowska Z.
    Acta Biochim Pol; 2017 Apr; 64(4):641-646. PubMed ID: 29141053
    [Abstract] [Full Text] [Related]

  • 12. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ, Oikonomou KG, Gibilaro E, Apergis G.
    Cancer Biomark; 2015 Apr; 15(6):725-34. PubMed ID: 26406401
    [Abstract] [Full Text] [Related]

  • 13. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients.
    Yam I, Lam DC, Chan K, Chung-Man Ho J, Ip M, Lam WK, Chan TK, Chan V.
    J Thorac Oncol; 2012 Jul; 7(7):1131-40. PubMed ID: 22610259
    [Abstract] [Full Text] [Related]

  • 14. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
    Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U.
    J Clin Oncol; 2003 Nov 01; 21(21):3902-8. PubMed ID: 14507943
    [Abstract] [Full Text] [Related]

  • 15. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi Y, Shomori K, Sano A, Kishimoto Y, Ito H, Hasegawa J, Shiota G.
    Cancer Sci; 2006 Dec 01; 97(12):1366-73. PubMed ID: 17052260
    [Abstract] [Full Text] [Related]

  • 16. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
    van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, van der Stappen JW, Dekhuijzen PN, van der Heijden HF, Thunnissen FB.
    Lung Cancer; 2010 May 01; 68(2):283-7. PubMed ID: 19632736
    [Abstract] [Full Text] [Related]

  • 17. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
    Katseli A, Maragos H, Nezos A, Syrigos K, Koutsilieris M.
    Clin Lung Cancer; 2013 Sep 01; 14(5):513-20. PubMed ID: 23810363
    [Abstract] [Full Text] [Related]

  • 18. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma.
    Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, Shimizu T, Ohsaki Y, Kikuchi K.
    Cancer; 2003 Sep 01; 98(5):1008-13. PubMed ID: 12942569
    [Abstract] [Full Text] [Related]

  • 19. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
    Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, Pérol M, Zavadil J, Brambilla C, Olivier M, Couraud S.
    Eur Respir J; 2015 Dec 01; 46(6):1773-80. PubMed ID: 26493785
    [Abstract] [Full Text] [Related]

  • 20. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
    Hetta HF, Zahran AM, El-Mahdy RI, Nabil EE, Esmaeel HM, Elkady OA, Elkady A, Mohareb DA, Mahmoud Mostafa M, John J.
    Asian Pac J Cancer Prev; 2019 Jun 01; 20(6):1927-1933. PubMed ID: 31244320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.